WA-TWIN-PROTOCOL
20.6.2024 09:31:27 CEST | Business Wire | Press release
Twin Protocol, a pioneer in the development of ethically engineered, personalized generative artificial intelligence (AI) technology to foster a culture of continuous knowledge sharing, announces a partnership with wellness and tech leaders, Cyberhuman.ai, and Dectec. The three companies are developing cutting-edge solutions that will democratize well-being and guide people around the world on the path of improved health and mindfulness. At the Cannes Creative Festival this week, Dr. Deepak Chopra unveils the first step in this revolutionary approach to sharing well-being knowledge across the globe – his Digital Deepak AI Twin.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240620183427/en/
Celebrating innovation at Cannes Creative Festival 2024: (pictured from left to right) Bill Inman, CEO of Dectec; Stacey Engle, CEO of Twin Protocol; Deepak Chopra, MD; and Poonacha Machaiah, Co-founder of Cyberhuman.ai., announce the groundbreaking Deepak Chopra AI Twin, a collaboration at the intersection of well-being, AI, and technology. (Photo: Business Wire)
World-renowned pioneer in integrative medicine and personal transformation, Dr. Deepak Chopra previews his digital twin to further his efforts to make chronic disease optional. Digital Deepak is a groundbreaking initiative to integrate advanced technology to more effectively, securely, and personally communicate his timeless wisdom, and guide people along the path of well-being and personal growth.
Interact with Dr. Chopra’s AI Twin here: Digital Deepak. Visitors can ask him questions from a subset of his published books and will even be treated to a sneak peek of his new “Digital Dharma” book, which focuses on the core role of AI in helping individuals achieve well-being and is scheduled for publication in December. Over the coming months, Dr. Chopra’s life’s work will be made available through his digital AI twin.
The partnership between Twin Protocol, Cyberhuman.ai, and Dectec is breaking new ground in the wellness industry. Cyberhuman.ai, an AI platform for personal health and well-being, optimizes lives for peak living at home, work, play, or on the road. The platform uses advanced diagnostics and predictive analytics to provide personalized well-being program recommendations. Dectec is creating the ecosystem and digital wallet that will enable users to make purchases within the ecosystem. Twin Protocol provides the decentralized digital AI twin technology for all healthcare gurus and users, the industry’s most secure, ultra-relatable means of sharing knowledge.
Dr. Chopra’s AI Twin, born out of extensive research and development by Twin Protocol, embodies his vision for guiding individuals on a journey pursuing optimal health and vitality. His AI Twin is poised to revolutionize the future of well-being by offering a holistic approach to wellness that integrates the latest security advancements in AI and blockchain technology. Future updates to the AI Twin will add new communication capabilities and modalities.
Dr. Deepak Chopra shared his perspective on the transformative potential of the AI Twin, stating, “With digital twins and AI technology, it is becoming possible to guide more and more people around the globe on a journey of ever-improving well-being and mindfulness. Over the coming weeks and months, I will share deeper insight through my twin, safely and securely empowering individuals to leverage my assistant as a confidant, health coach, and spiritual guide.”
“The launch of Dr. Deepak Chopra’s AI Twin demonstrates the exceptional vision and capabilities of the Cyberhuman.ai, Dectec, and Twin Protocol team. This is a significant milestone in our journey towards empowering individuals to live their best, most healthy lives,” said Stacey Engle, CEO of Twin Protocol. “By combining cutting-edge technology with his profound wisdom, we are pioneering a new paradigm of well-being that is accessible, personalized, and transformative.”
A unique panel will take place this week at Cannes, exploring the transformative potential of AI and digital twins in enhancing individual well-being.
June 20, 2024
11:00 AM to 12:00 PM
Annex Beach Cannes
Boulevard de la Croisette, Cannes - France
Participants:
- Deepak Chopra – MD
- Poonacha Machaiah – Co-founder, Cyberhuman.ai
- Stacey Engle – CEO, Twin Protocol
- Bill Inman – CEO, Dectec
“AI is reinventing aspects of our world in fundamental ways, including enabling us to create a future where people around the globe can instantly harness the well-being knowledge and insights of global thought leaders such as Dr. Chopra,” said Poonacha Machaiah, co-founder of Cyberhuman.ai. “Through partnerships with world-leading tech innovators like Twin Protocol and Dectec, we are democratizing well-being and helping people live their best lives.”
“When it comes to wellness and health-related information and transactions, its essential that our data is absolutely secure,” said Bill Inman, CEO, Dectec. “With our Web3 platform and collaboration with world-class partners, we’re creating a secure ecosystem that protects users and empowers them to securely manage and improve all aspects of their well-being.”
For more information about Twin Protocol, please visit Twin Protocol.
About Cyberhuman.ai
Cyberhuman.ai is a pioneering advance in personal health and well-being. It is designed as an AI platform to help individuals optimize their lives for peak living across various environments—at home, work, play, or on the road. Leveraging a combination of advanced diagnostics and predictive analytics, the platform offers personalized well-being program recommendations.
About Dectec
Dectec is a pioneering Web3 platform that connects traditional enterprises with advanced AI and blockchain technologies. Specializing in loyalty and rewards programs, Dectec empowers businesses to expand their reach and deepen customer engagement through innovative solutions like user-friendly mobile apps, metaverse experiences, and robotics. The company’s strategy focuses on tapping into new markets with a sophisticated, user-centric wallet system, ensuring clients stay at the forefront of industry innovation for sustained success.
About Twin Protocol
The mission of Twin Protocol’s global venture is to empower individuals and organizations to create secure, dynamic digital versions of themselves to share knowledge, create legacies, and foster continuous learning. Through an advanced AI and blockchain ecosystem, Twin Protocol is revolutionizing the way knowledge and expertise are preserved, shared, and utilized. Twin Protocol, along with strategic partners including SingularityNET, is committed to helping users shape a future where knowledge is an enduring and shared asset. Learn more at Twin Protocol.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240620183427/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Fujirebio Expands Access in Canada to Blood-based Neurology Testing with Health Canada Class II Medical Device Licenses for the Lumipulse® G NfL Blood and Lumipulse G pTau 217 Plasma Assays1.9.2026 07:00:00 CEST | Press release
H.U. Group Holdings Inc. and its wholly owned subsidiary Fujirebio today announced that Health Canada has issued Class II Medical Device Licenses (MDL) for the Lumipulse G NfL Blood and the Lumipulse G pTau 217 Plasma assay for use on the fully automated LUMIPULSE® G immunoassay platform in the Canadian market. "The approval of the Lumipulse G NfL Blood and Lumipulse G pTau 217 Plasma assays for clinical use in Canada marks another important step in our mission to expand access to reliable and clinically meaningful blood-based biomarkers for clinicians and patients worldwide," said Christiaan De Wilde, CEO of Fujirebio Europe N.V. “As a pioneer in neurological diagnostics, Fujirebio remains committed to advancing patient care through innovative, fully automated testing solutions." These approvals further strengthen Fujirebio’s comprehensive neurological diagnostics portfolio by broadening access to high-quality biomarker solutions designed to inform clinical decision-making across the
Helical Fusion Named a Final Candidate for Japan’s METI Fusion Power Demonstration Program1.9.2026 04:00:00 CEST | Press release
Milestone-based government program supports multiple fusion approaches toward power demonstration and commercialization Helical Fusion Co., Ltd., a fusion energy company developing a Helical Stellarator toward commercially viable fusion power, has been named a final candidate for Japan’s Ministry of Economy, Trade and Industry (METI) program supporting the demonstration of fusion power generation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260831991676/en/ Image of Helix HARUKA, Helical Fusion’s Integrated Demo Device(left), and Helix KANATA, Helical Fusion’s Fusion Pilot Plant(right) The program is designed to accelerate fusion power demonstration in the 2030s under Japan’s national energy and fusion strategies. It supports private-sector technology development across multiple fusion approaches, including tokamak, stellarator and laser fusion, with approximately JPY 60 billion in total government support anticipated ove
Strategic Combination of ITC Infotech and Happiest Minds Technologies to Create a Scaled, Future-Ready, AI-First Global Technology Services Enterprise with US$ 1 Billion Revenue by FY28[1]31.8.2026 23:35:00 CEST | Press release
ITC Infotech Board approves proposed acquisition of 22.1% promoter stake and a Scheme of Amalgamation of the two companies ITC Infotech (ITCI), a wholly owned subsidiary of ITC Limited and a leading global technology services player, today announced the proposed strategic combination with Happiest Minds Technologies Limited (Happiest Minds) to create a scaled, future-ready, AI-first global technology services enterprise. The ITCI Board approved a proposal to acquire 22.1% equity stake from the promoter of Happiest Minds in two tranches under a Share Purchase Agreement. The transaction would be funded through a Rights Issue by ITC Infotech. ITCI Board has also approved a proposed Scheme of Amalgamation of Happiest Minds with ITCI which will be effected after the share acquisition. Pursuant to the scheme, the shares of ITCI will be listed on the stock exchanges. The proposed transaction has also been endorsed by the Board of Directors of ITC Limited. This strategic combination will syner
Angel’s Profits Grew Robustly in the First Half of 2026 with Europe and North America Turning Profitable Ahead of Schedule31.8.2026 21:07:00 CEST | Press release
Angelalign Technology Inc. (“Angel” or the “Company”) (6699.HK) (angelaligner.com), the second largest clear aligner supplier by revenue, announced today that its revenue grew 42.9% to US$230.7 million and net profit grew 79.6% to $25.5 million for the six months ending June 30, 2026. Angel’s business in Europe and North America crossed into profitability ahead of plan while the business in Chinese mainland delivered market share gains well above expectations. Doctors and staff in every region report that they are increasingly selecting Angel’s solutions after experiencing more predictable outcomes, especially on complex cases, and embracing the positive culture of the company. Dr. Mark Holt D.D.S., M.S. of Holt Orthodontics in Northern California, states: “We treat over half of our patients with clear aligners and our experience with Angel’s treatment plans and clear aligners has been tremendous.” “Our main focus is to provide great service to and being a rock-solid partner for our cu
BeOne Medicines Announces Voluntary Agreement with U.S. Government to Expand Access to Innovative Cancer Medicines31.8.2026 21:00:00 CEST | Press release
Agreement advances patient access and strengthens BeOne's long-term commitment to U.S. innovation and manufacturing BeOne Medicines, Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced a voluntary agreement with the U.S. Government to expand access to innovative cancer medicines for American patients while strengthening our U.S manufacturing footprint and further expanding the capabilities needed to deliver medicines at scale. The agreement builds on BeOne's longstanding commitment to patient access and investment in research and scientific innovation. John V. Oyler, Co-Founder, Chairman and CEO, BeOne Medicines, said: “At BeOne, we believe every patient should benefit from innovative cancer therapies. We appreciate the Trump Administration’s commitment to advancing solutions that broaden access and scientific progress for American patients. This agreement reflects our purpose to reach more patients as we expand our U.S. investment in additional res
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom